title: Decreased CNS inflammation and absence of clinical exacerbation of disease after six months oral administration of bovine myelin in diseased SJL/J mice with chronic relapsing experimental autoimmune encephalomyelitis.
abstract: Murine chronic relapsing experimental autoimmune encephalomyelitis (CR-EAE) is a model of inflammatory demyelinating disease of the central nervous system (CNS) with similarity to multiple sclerosis (MS) in humans. Mice with confirmed neurologic deficits from CR-EAE were treated by oral administration of whole bovine myelin to investigate the effect of long-term oral delivery of myelin antigens on clinical disease and on the inflammatory response in the CNS. EAE-positive mice were fed doses of 1 mg, 10 mg, or 20 mg of bovine myelin every other day for 6 months. We found that prolonged oral delivery of neuroantigen suppressed inflammatory and demyelination foci in the CNS of myelin-treated mice with no exacerbation of clinical disease status compared with the control group. Analysis of histologic sections of brain and spinal cords with hematoxylin-eosin (H&E) and Luxol fast blue (LFB) staining showed a decrease in the inflammatory cell infiltration and active centers of demyelination, respectively. Furthermore, after 6 months of treatment, there was no increased sensitization to myelin antigens seen, as measured by antimyelin basic protein (MBP) or anti-proteolipid apoprotein (PLP) antibodies. These results demonstrate that prolonged oral administration of myelin antigens in diseased animals has an ameliorating effect on the pathologic process and supports its potential long-term use in humans with MS.
authors.affiliation: AutoImmune Inc, Lexington, MA 02173, USA. aimm@world.std.com
authors.forename: A M
authors.initials: AM
authors.lastname: al-Sabbagh
authors.forename: E P
authors.initials: EP
authors.lastname: Goad
authors.forename: H L
authors.initials: HL
authors.lastname: Weiner
authors.forename: P A
authors.initials: PA
authors.lastname: Nelson
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D002417:Cattle; D002908:Chronic Disease; D003711:Demyelinating Diseases / Q000276:immunology; D018450:Disease Progression; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000276:immunology*; D005260:Female; D051379:Mice; D008815:Mice, Inbred Strains; D004676:Myelin Basic Protein / Q000276:immunology / Q000494:pharmacology*; D018991:Myelin Proteolipid Protein / Q000276:immunology / Q000494:pharmacology*; D012008:Recurrence; D013997:Time Factors
chemical_list: D004676:Myelin Basic Protein; D018991:Myelin Proteolipid Protein